Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16777| Title: | A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant | Austin Authors: | Davis, Ian D;Quirk, Juliet;Morris, Leone;Seddon, Lauren;Tai, Tsin Yee;Whitty, Genevieve;Cavicchiolo, Tina;Ebert, Lisa;Jackson, Heather;Browning, Judy;MacGregor, Duncan;Wittke, Frederick;Winkels, Gregor;Alex, Regina;Miloradovic, Lena;Maraskovsky, Eugene;Chen, Weisan;Cebon, Jonathan S | Affiliation: | Ludwig Institute for Cancer Research, Victoria, Australia Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Monash University Eastern Health Clinical School, Box Hill, Victoria, Australia Eastern Health, Victoria, Australia Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia Miltenyi Biotec, Germany CSL Limited, Melbourne, Victoria, Australia School of Cancer Medicine, La Trobe University, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia |
Issue Date: | Mar-2017 | Date: | 2017-02-10 | Publication information: | Immunotherapy 2017; 9(3): 249-259 | Abstract: | Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. CONCLUSION: This method was feasible and safe but was minimally immunogenic. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16777 | DOI: | 10.2217/imt-2016-0132 | Journal: | Immunotherapy | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/28183192 | Type: | Journal Article | Subjects: | ISCOMATRIX™ adjuvant NY-ESO-1 Antigens Clinical trial Dendritic cells |
Type of Clinical Study or Trial: | Clinical Trial |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.